BridgeBio announces first participant dosed in ASCEND-ATTR
BridgeBio said the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study evaluating the long-term effects of acoramidis on disease regression in ATTR-CM.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.